TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03204890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation
Description: Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
Study: NCT03439670

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of 6.0 mg/kg/day for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral administration of 0.75 mg/kg/day for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo daily for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vamorolone
Description: Oral administration of 2.0 mg/kg/day for 20 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vamorolone
Description: Oral administration of 2.0 mg/kg/day for 20 weeks.
Study: NCT02761356

Intervention type: OTHER
Intervention: Tc99-MAA
Description: To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies

Intervention type: OTHER
Intervention: Tc99-MAA
Description: To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
Study: NCT00997750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Description: lornoxicam 8mg/day and 12mg/day for 15 days
Study: NCT03333317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive oral administration of lumicitabine.
Study: NCT04725266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based intervention
Description: The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 17 sessions will be delivered with 1.5-2 hour for each session (6 sessions for Engagement, 3 sessions for Role identification, 3 sessions for Affection, and 3 sessions for Competence).
Study: NCT03333317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive oral administration of lumicitabine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral administration of matching placebo.
Study: NCT04725266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine care
Description: Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
Study: NCT03393559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leg elevation
Description: Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
Study: NCT00978718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-selenium baker's yeast
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT05479565

Intervention type: DIAGNOSTIC_TEST
Intervention: venous blood sample for determining the value of highly sensitive C-reactive C protein from serum
Description: The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.

Intervention type: DIAGNOSTIC_TEST
Intervention: venous blood sample for determining the value of highly sensitive C-reactive C protein from serum
Description: The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
Study: NCT04024982

Intervention type: OTHER
Group type: OTHER
Intervention: Sequence of teaching (Lecture first followed by Simulation)
Description: Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.

Intervention type: OTHER
Group type: OTHER
Intervention: Sequence of teaching (Simulation first followed by Lecture)
Description: Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
Study: NCT04711291

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conversion to Envarsus-XR and use of smart phone app, TransMedAx
Description: Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Convert to Envarsus XR once daily
Description: Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
Study: NCT01905566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg once a day
Study: NCT02142673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 80
Description: The hysteroscope filling pressure will be 80mm Hg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 60
Description: The hysteroscope filling pressure will be reduced to 50mm Hg
Study: NCT02763436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiological-based cord clamping
Description: The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
Study: NCT02947399

Intervention type: RADIATION
Group type: OTHER
Intervention: Radioactive Iodine 124
Description: After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
Study: NCT01278407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Description: Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Description: Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Description: Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Description: Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil matched placebo
Study: NCT00885794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 3 intravitreal injection every 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 3 intravitreal injection every 5 weeks
Study: NCT01415804

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: endoprosthesis
Description: Thoracic aortic stentgraft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoprosthesis
Description: Thoracic aortic stentgraft
Study: NCT03545711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride with Irinotecan
Description: Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
Study: NCT02142673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 40
Description: The hysteroscope filling pressure will be 40mm Hg
Study: NCT03693391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 Labeled [18F]-JNJ-64511070
Description: An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 Labeled [18F]-JNJ-64511070
Description: An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 Labeled [18F]-JNJ-64511070
Description: An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 Labeled [18F]-JNJ-64511070
Description: An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
Study: NCT01905566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg twice a day
Study: NCT02232737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Study: NCT02335632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics (Lacidofil®)
Description: 7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For probiotics
Study: NCT03507504

Intervention type: OTHER
Intervention: SCU-B
Description: SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home.
Study: NCT01840085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03% DSC127 topical gel
Study: NCT03871075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic compression
Description: Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic compression
Description: Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
Study: NCT00243412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
Study: NCT03871075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham device
Description: The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham device
Description: The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
Study: NCT01567852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methohexital
Description: Methohexital (1.5mg/kg) will be given for induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methohexital
Description: Methohexital (1.5mg/kg) will be given for induction
Study: NCT00243412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 500 mg or 1000 mg IV\*2.
Study: NCT00386399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Description: Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
Study: NCT04674605

Intervention type: DEVICE
Intervention: biomarkers
Description: biomarkers

Intervention type: DEVICE
Intervention: biomarkers
Description: biomarkers
Study: NCT03799588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic Chest Cuirass
Description: Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
Study: NCT02637063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BlipHub mobile-web app
Description: Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BlipHub mobile-web app + health coaching
Description: Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: No intervention beyond participants' own medical care.
Study: NCT03555110

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personality Factor Battery Test (PFB Test)
Description: Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing Therapy (EMDR)
Description: It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory.
Study: NCT04235998

Intervention type: DIAGNOSTIC_TEST
Intervention: Systematic lung ultrasound
Description: Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment.
Study: NCT01523002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol and pyronaridine-artesunate
Description: On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyronaridine-artesunate
Description: On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period.
Study: NCT05741177

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: lung ultrasound score
Study: NCT03280381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nifty feeding cup
Description: The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.